WO2016108123A3 - Pure amorphous and amorphous solid dispersion of ceritinib - Google Patents
Pure amorphous and amorphous solid dispersion of ceritinib Download PDFInfo
- Publication number
- WO2016108123A3 WO2016108123A3 PCT/IB2015/059657 IB2015059657W WO2016108123A3 WO 2016108123 A3 WO2016108123 A3 WO 2016108123A3 IB 2015059657 W IB2015059657 W IB 2015059657W WO 2016108123 A3 WO2016108123 A3 WO 2016108123A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amorphous
- ceritinib
- solid dispersion
- pure
- amorphous solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present application relates to pure amorphous form of ceritinib and process for preparation thereof. Another aspect of the present application relates to amorphous solid dispersion of ceritinib and process for preparation thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN6355CH2014 | 2014-12-17 | ||
IN6355/CHE/2014 | 2014-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016108123A2 WO2016108123A2 (en) | 2016-07-07 |
WO2016108123A3 true WO2016108123A3 (en) | 2016-08-18 |
Family
ID=56285108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/059657 WO2016108123A2 (en) | 2014-12-17 | 2015-12-16 | Pure amorphous and amorphous solid dispersion of ceritinib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016108123A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022061120A1 (en) * | 2020-09-18 | 2022-03-24 | Dispersol Technologies, Llc | Solid dispersions containing amorphous nintedanib, their synthesis and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012082972A1 (en) * | 2010-12-17 | 2012-06-21 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
-
2015
- 2015-12-16 WO PCT/IB2015/059657 patent/WO2016108123A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012082972A1 (en) * | 2010-12-17 | 2012-06-21 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
Also Published As
Publication number | Publication date |
---|---|
WO2016108123A2 (en) | 2016-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3191584A4 (en) | Methods of producing mogrosides and compositions comprising same and uses thereof | |
WO2016011222A3 (en) | Circular polynucleotides | |
EP3532633A4 (en) | Compositions and methods for the production of compounds | |
WO2016001885A3 (en) | Amorphous form of eliglustat hemitartarate | |
EP3325608A4 (en) | Methods and microorganisms for the production of 1,3-butanediol | |
WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
EP3294450A4 (en) | Process to produce modified clay, modified clay produced and use thereof | |
WO2016009401A3 (en) | Preparation of tedizolid phosphate | |
WO2015191945A3 (en) | Solid state forms of sofosbuvir | |
WO2015092810A3 (en) | Amorphous form of idelalisib | |
EP3280408A4 (en) | Process for the preparation of dicycloplatin | |
WO2016038542A3 (en) | Solid forms of sofosbuvir | |
EP3221843A4 (en) | Efficient methodology to process wide dynamic range images | |
EP3694499A4 (en) | Novel process for the preparation of lifitegrast | |
WO2018069941A3 (en) | Polymorphic forms of venetoclax | |
EP3094341A4 (en) | Enolase 1 (eno1) compositions and uses thereof | |
EP3642415A4 (en) | Nanolignocellulose compositions and processes to produce these compositions | |
EP3532055A4 (en) | Compositions and methods for the production of compounds | |
EP3227298A4 (en) | Process for the preparation of baricitinib and an intermediate thereof | |
WO2016108206A3 (en) | Processes for preparation of idelalisib and intermediates thereof | |
EP3720845A4 (en) | Processes to produce elagolix | |
EP3389632A4 (en) | Amorphous onapristone compositions and methods of making the same | |
EP3016935A4 (en) | Process for the preparation of intermediate of dolutegravir | |
EP2989056A4 (en) | Nanoiron suspension, process for the preparation thereof its use and device for the preparation of nanoiron suspension | |
WO2016063289A3 (en) | Pharmaceutical tablet compositions comprising rifaximin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15875323 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15875323 Country of ref document: EP Kind code of ref document: A2 |